Chardan Capital Reiterates Buy Rating for SAB Biotherapeutics
Chardan Capital keeps its buy rating on SAB Biotherapeutics with a $16 price target, a 307.12% upside from the current price.
Key Points
- Chardan Capital reiterated its buy rating on SAB Biotherapeutics, Inc. (SABS) with a $16 price target on June 17, 2026.
- Chardan Capital's $16 price target implies 307.12% upside from SAB Biotherapeutics, Inc.'s ($SABS) current $3.93 share price.
- Shares of SABS traded at $3.66, with a market cap of about $279.9 million and a 52-week range between $1.67 and $6.60.
- Institutional investors like Perceptive Advisors LLC increased their holdings significantly, reflecting ongoing interest in the company's potential.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Chardan Capital has reiterated its buy rating on SAB Biotherapeutics, Inc. (NasdaqCM: SABS) with a price target of $16. This reaffirmation by analyst Keay Nakae on June 17, 2026, suggests continued confidence in the company's growth prospects. Shares were trading at $3.66 on the same day.
SAB Biotherapeutics, Inc. Stock Up 3.7%
Shares of NasdaqCM:SABS were trading near $3.66. SAB Biotherapeutics has a market cap of approximately $279.9 million and a forward P/E ratio that is not meaningful as the company is not currently profitable. The stock's 52-week range is between $1.67 and $6.60, with a 50-day moving average of $3.68 and a 200-day moving average of $3.49. The company maintains a strong liquidity position with a current ratio of 11.45 and a quick ratio of 11.06, while its debt-to-equity ratio stands at 2.72.
$SABS price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Other Institutional Activity in SAB Biotherapeutics
Perceptive Advisors LLC significantly increased its holdings in SAB Biotherapeutics by 5,628,533 shares, ending with 6,431,743 shares valued at about $24.63 million. Meanwhile, Caligan Partners LP entered a new position with 7,967,207 shares worth approximately $30.51 million. Balyasny Asset Management L.P. also boosted its stake by 3,285,000 shares, now holding 3,760,439 shares valued around $14.40 million. Other funds like Vivo Capital, RA Capital Management, and Commodore Capital maintained their positions without changes.
Insider Buying and Selling at SAB Biotherapeutics, Inc.
Notable insider transactions include Chief Financial Officer Lucy To acquiring 2,400,000 shares on February 3, 2026, and Chief Operating Officer Christoph Lawrence Bausch purchasing 1,800,000 shares on the same date. CEO Samuel Reich also bought 4,800,000 shares on February 3, 2026. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
On June 17, 2026, Chardan Capital maintained its buy rating on SAB Biotherapeutics with a $16 price target. Leerink Partners and HC Wainwright & Co. also maintained buy ratings with targets of $12 and $10, respectively, on June 15. Citigroup initiated coverage with a buy rating and an $11 target on May 22. The consensus among 10 analysts is a strong buy, with an average target price of $10.60.
About SAB Biotherapeutics
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company based in Miami Beach, Florida. It focuses on developing human polyclonal immunotherapeutic antibodies aimed at treating immune system disorders and infectious diseases. Its key product, SAB-142, is under clinical development for autoimmune type 1 diabetes, currently in Phase 2b trials. Founded in 2014, the company is led by CEO Samuel J. Reich and employs 86 people.
Bottom Line
Chardan Capital's reiteration of its buy rating for SAB Biotherapeutics reflects ongoing optimism about the company's future. With a strong liquidity position and active institutional interest, SAB Biotherapeutics remains a company to watch. Keep in mind that analyst ratings and 13F filings are backward-looking and may not reflect current market conditions.
Get SAB Biotherapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SABS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.